- Advertisement -
- Advertisement -

Related

Rhenman & Partners Strengthening Their Ranks

Latest Report

- Advertisement -

Stockholm (HedgeNordic) – Rhenman & Partners is expanding its portfolio management team with the addition of Camilla Oxhamre Cruse as the fourth portfolio manager, with a primary focus on pharmaceutical development companies. Starting in early September, Cruse will join the four-member investment team led by founder and CIO Henrik Rhenman.

Cruse has spent the last ten years in London, most recently as a senior healthcare analyst and assistant portfolio manager at Newton Investment Management. Her career also includes a seven-and-a-half-year tenure at William Blair & Company as a senior research analyst covering the global healthcare sector. Prior to her time in London, Cruse was a senior equity analyst at Carnegie Investment Bank in Stockholm, focusing on healthcare. She holds a master’s degree in biochemistry from Lund University, a doctorate in medicine from Karolinska Institute, and an MBA from Hawaii Pacific University in the United States.

“Camilla’s long international background and broad expertise in the medical field and her experience in the financial markets will be a strong addition to our organization.”

Henrik Rhenman, founder and CIO at Rhenman & Partners.

“We are very pleased that Camilla will become part of Rhenman & Partners,” says Henrik Rhenman, founder and CIO at Rhenman & Partners. “Camilla’s long international background and broad expertise in the medical field and her experience in the financial markets will be a strong addition to our organization,” he continues. “Camilla will work closely with the entire investment team, focusing on the biotech and pharmaceutical sub-sectors where we continue to see great potential.” 

“It is a company that I have followed for a long time and that has impressed me with its in-depth fundamental analysis in the healthcare sector, integrity and skillful management, which has led to a long track record of positive returns.”

Camilla Oxhamre Cruse

“I look forward to joining Rhenman & Partners,” comments Camilla Oxhamre Cruse. “It is a company that I have followed for a long time and that has impressed me with its in-depth fundamental analysis in the healthcare sector, integrity and skillful management, which has led to a long track record of positive returns,” she adds. “I am really pleased to become part of the team and to be able to contribute with my many years of analytical experience of the global pharmaceutical sector.”

Cruse will work alongside portfolio managers Kaspar Hållsten, Hugo Schmidt, and Amennai Beyeen, under the leadership of CIO Henrik Rhenman, to manage the Rhenman Healthcare Equity L/S fund. Since its launch in mid-2009, the fund has delivered an annualized return of 16.6 percent for the share class represented in the Nordic Hedge Index. The fund has gained 17.1 percent in the first seven months of 2024.

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

Tidan to Launch Confluence, Its Integrated Multi-Strategy Fund

Stockholm-based Tidan Capital is preparing to launch Confluence, a new multi-strategy vehicle that brings the boutique’s internally managed strategies under one umbrella. The fund,...

State Pension Fund of Finland Sees Strong Hedge Fund Gains

The first half of 2025 brought a complex market backdrop shaped by shifting macroeconomic trends, tariffs, geopolitical uncertainty, and volatile investor sentiment. Although returns...

Espiria Rolls Out Long-Only Fund Led by Staffan Östlin

After more than a decade of picking stocks on both the long and short side, veteran fund manager Staffan Östlin is now running a...

The “Magic of Three”: Protean Select Turns Milestone into Major Allocation

Reaching the three-year mark is a key milestone and often a turning point for any emerging hedge fund. For Protean Select, the opportunistic equity...

Twelve Years On, Nordkinn Expands with Two PMs and Advisor

Twelve years after its inception, Nordkinn Asset Management is entering a new growth phase, expanding its investment team with the appointments of Arian Kalantari...

Merger Cleared: Carlsson Norén to Transition Funds to UCITS

After nearly two decades as an independent fund manager, Carlsson Norén Asset Management is joining Meriti Capital, following regulatory approval from Finansinspektionen. Its two...

Allocator Interviews

In-Depth: High Yield

Voices

Request for Proposal

- Advertisement -
HedgeNordic
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.